BridgeBio Pharma (NASDAQ:BBIO) Director Sells $1,442,028.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 17,167 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the sale, the director owned 22,579 shares in the company, valued at $1,896,636. This represents a 43.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $82.66 on Thursday. BridgeBio Pharma, Inc. has a one year low of $42.09 and a one year high of $93.42. The company has a market cap of $16.19 billion, a P/E ratio of -22.10 and a beta of 0.95. The firm has a 50 day simple moving average of $70.60 and a two-hundred day simple moving average of $72.22.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.51 million during the quarter, compared to analysts’ expectations of $178.07 million. During the same period in the previous year, the firm earned ($0.88) EPS. BridgeBio Pharma’s revenue was up 66.8% on a year-over-year basis. On average, analysts expect that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

BBIO has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Canaccord Genuity Group started coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 target price for the company. Citigroup started coverage on shares of BridgeBio Pharma in a research note on Tuesday, May 19th. They issued a “neutral” rating and a $82.00 price target on the stock. Truist Financial upped their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, HC Wainwright increased their price objective on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.63.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $120 price target on BridgeBio Pharma, while raising several longer-term earnings estimates, including FY2027 EPS to $2.19. This supports the view that analysts still see substantial upside potential. BridgeBio Pharma analyst report
• Positive Sentiment: HC Wainwright also increased its Q4 2026, Q2 2027, Q3 2027, and Q4 2027 EPS forecasts, suggesting improving expectations for BridgeBio’s profitability over time. BridgeBio Pharma analyst report
• Neutral Sentiment: The analyst slightly lowered near-term estimates for Q3 2026 and Q1 2027 EPS and trimmed FY2026 EPS, reflecting some caution on the company’s shorter-term earnings trajectory. BridgeBio Pharma analyst report
• Negative Sentiment: Director Andrea Ellis sold 17,167 shares worth about $1.44 million, a disclosure that can weigh on investor sentiment even though the trade was made under a pre-arranged 10b5-1 plan. Insider selling article

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently bought and sold shares of BBIO. HighVista Strategies LLC raised its position in shares of BridgeBio Pharma by 21.4% during the third quarter. HighVista Strategies LLC now owns 81,959 shares of the company’s stock worth $4,257,000 after acquiring an additional 14,460 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in BridgeBio Pharma by 14,211.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 994,220 shares of the company’s stock worth $77,783,000 after purchasing an additional 987,273 shares during the period. Central Pacific Bank Trust Division bought a new stake in BridgeBio Pharma in the fourth quarter valued at $789,000. Geode Capital Management LLC raised its holdings in shares of BridgeBio Pharma by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock valued at $344,689,000 after purchasing an additional 502,582 shares during the period. Finally, Nan Fung Trinity HK Ltd. acquired a new position in shares of BridgeBio Pharma during the fourth quarter valued at about $8,422,000. 99.85% of the stock is currently owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.